Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable success in hematological malignancies but remains ineffective in solid tumors, due in part to CAR T cell exhaustion in the solid tumor microenvironment. To study dysfunction of mesothelin-redirected CAR T cells in pancreatic cancer, we establish a robust model of continuous antigen exposure that recapitulates hallmark features of T cell exhaustion and discover, both in vitro and in CAR T cell patients, that CAR dysregulation is associated with a CD8+ T-to-NK-like T cell transition. Furthermore, we identify a gene signature defining CAR and TCR dysregulation and transcription factors, including SOX4 and ID3 as key regulators of CAR T&nbs...
Background: T cells expressing chimeric antigen receptors (CARs) have shown exciting promise in canc...
Chimeric antigen receptor (CAR)-T cell therapy is rapidly advancing as cancer treatment, however, de...
International audienceAdoptive transfer of T cells genetically engineered to express chimeric antige...
Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable success in hematological...
CAR-T cell therapy has emerged as a promising cancer treatment modality with curative potential. In ...
In this issue of Cancer Cell, Zhao and colleagues test various chimeric antigen receptor (CAR) T cel...
Exhaustion of chimeric antigen receptor (CAR)-T cells hinders their therapeutic efficacy, especially...
T cells engineered to express chimeric antigen receptors (CARs) targeting CD19 have produced impress...
In this issue of Cancer Cell, Zhao and colleagues test various chimeric antigen receptor (CAR) T cel...
Chimeric Antigen Receptor (CAR) T cell therapies for hematologic malignancies have been astonishingl...
© 2016 Dr Alexander DavenportDespite the success of autologous chimeric antigen receptor (CAR) T cel...
Immunotherapy using chimeric antigen receptor (CAR) T cells is a promising option for cancer treatme...
Chimeric antigen receptor (CAR) therapy is based on patient blood-derived T cells and natural killer...
Adoptive T-cell therapy has emerged as one of the most promising treatment modalities for cancer. CD...
Chimeric antigen receptor (CAR) development is biased toward selecting constructs that elicit the hi...
Background: T cells expressing chimeric antigen receptors (CARs) have shown exciting promise in canc...
Chimeric antigen receptor (CAR)-T cell therapy is rapidly advancing as cancer treatment, however, de...
International audienceAdoptive transfer of T cells genetically engineered to express chimeric antige...
Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable success in hematological...
CAR-T cell therapy has emerged as a promising cancer treatment modality with curative potential. In ...
In this issue of Cancer Cell, Zhao and colleagues test various chimeric antigen receptor (CAR) T cel...
Exhaustion of chimeric antigen receptor (CAR)-T cells hinders their therapeutic efficacy, especially...
T cells engineered to express chimeric antigen receptors (CARs) targeting CD19 have produced impress...
In this issue of Cancer Cell, Zhao and colleagues test various chimeric antigen receptor (CAR) T cel...
Chimeric Antigen Receptor (CAR) T cell therapies for hematologic malignancies have been astonishingl...
© 2016 Dr Alexander DavenportDespite the success of autologous chimeric antigen receptor (CAR) T cel...
Immunotherapy using chimeric antigen receptor (CAR) T cells is a promising option for cancer treatme...
Chimeric antigen receptor (CAR) therapy is based on patient blood-derived T cells and natural killer...
Adoptive T-cell therapy has emerged as one of the most promising treatment modalities for cancer. CD...
Chimeric antigen receptor (CAR) development is biased toward selecting constructs that elicit the hi...
Background: T cells expressing chimeric antigen receptors (CARs) have shown exciting promise in canc...
Chimeric antigen receptor (CAR)-T cell therapy is rapidly advancing as cancer treatment, however, de...
International audienceAdoptive transfer of T cells genetically engineered to express chimeric antige...